Simian adenoviruses as vaccine vectors

Future Virology

Volumn 11, Issue 9, 2016, Pages 649-659

  Morris, Susan J ^a   Sebastian, Sarah ^a   Spencer, Alexandra J ^a   Gilbert, Sarah C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

BAC recombineering; chimpanzee adenoviruses; clinical trials; simian adenoviruses; vector vaccine

Indexed keywords

ADENOVIRUS VACCINE; ADENOVIRUS VECTOR; ANTIGEN; EBOLA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MALARIA VACCINE; PROTEIN; VIRUS LIKE PARTICLE VACCINE;

CLINICAL TRIAL (TOPIC); HUMAN; HUMAN ADENOVIRUS 5; IMMUNE RESPONSE; IMMUNOGENICITY; PRIORITY JOURNAL; REVIEW; SEROPREVALENCE; SIMIAN VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

EID: 84988592787     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl-2016-0070     Document Type: Review

References (66)

1. Nwanegbo E, Vardas E, Gao W, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol. 11(2), 351-357 (2004
2. Dudareva M, Andrews L, Gilbert SC, et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 27(27), 3501-3504 (2009
3. Zhang S, Huang W, Zhou X, Zhao Q, Wang Q, Jia B. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J. Med. Virol. 85(6), 1077-1084 (2013
4. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653), 1881-1893 (2008
5. Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 194(12), 1638-1649 (2006
6. Priddy FH, Brown D, Kublin J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis. 46(11), 1769-1781 (2008
7. Xiang Z, Li Y, Cun A, et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg. Infect. Dis. 12(10), 1596-1599 (2006
8. Ersching J, Hernandez MI, Cezarotto FS, et al. Neutralizing antibodies to human and simian adenoviruses in humans and new-world monkeys. Virology 407(1), 1-6 (2010
9. Abbink P, Maxfield LF, Nganga D, et al. Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors. J. Virol. 89(3), 1512-1522 (2015
10. Duncan M, Cranfield MR, Torano H, et al. Adenoviruses isolated from wild gorillas are closely related to human species C viruses. Virology 444(1-2), 119-123 (2013
11. Roy S, Medina-Jaszek A, Wilson MJ, et al. Creation of a panel of vectors based on ape adenovirus isolates. J. Gene Med. 13(1), 17-25 (2011
12. Colloca S, Barnes E, Folgori A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl. Med. 4(115), 115ra112 (2012
13. Tatsis N, Tesema L, Robinson ER, et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther. 13(5), 421-429 (2006
14. Farina SF, Gao GP, Xiang ZQ, et al. Replication-defective vector based on a chimpanzee adenovirus. J. Virol. 75(23), 11603-11613 (2001
15. Roy S, Gao G, Clawson DS, Vandenberghe LH, Farina SF, Wilson JM. Complete nucleotide sequences and genome organization of four chimpanzee adenoviruses. Virology 324(2), 361-372 (2004
16. Roy S, Gao G, Lu Y, et al. Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. Hum. Gene Ther. 15(5), 519-530 (2004
17. Bauza K, Malinauskas T, Pfander C, et al. Efficacy of a plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites. Infect. Immun. 82(3), 1277-1286 (2014
18. Reyes-Sandoval A, Sridhar S, Berthoud T, et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur. J. Immunol. 38(3), 732-741 (2008
19. Goodman AL, Epp C, Moss D, et al. New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1. Infect. Immun. 78(11), 4601-4612 (2010
20. Fitzgerald JC, Gao GP, Reyes-Sandoval A, et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 170(3), 1416-1422 (2003
21. Pinto AR, Fitzgerald JC, Gao GP, Wilson JM, Ertl HC. Induction of CD8+ T cells to an HIV-1 antigen upon oral immunization of mice with a simian E1-deleted adenoviral vector. Vaccine 22(5-6), 697-703 (2004
22. Roy S, Kobinger GP, Lin J, et al. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine 25(39-40), 6845-6851 (2007
23. Kobinger GP, Feldmann H, Zhi Y, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 346(2), 394-401 (2006
24. Fattori E, Zampaglione I, Arcuri M, et al. Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes. Gene Ther. 13(14), 1088-1096 (2006
25. Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci. Transl. Med. 4(115), 115ra111 (2012
26. Zhou D, Cun A, Li Y, Xiang Z, Ertl HC. A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Mol. Ther. 14(5), 662-672 (2006
27. Warimwe GM, Lorenzo G, Lopez-Gil E, et al. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. Virol. J. 10, 349 (2013
28. Ruzsics Z, Lemnitzer F, Thirion C. Engineering adenovirus genome by bacterial artificial chromosome (BAC) technology. Methods Mol. Biol. (Clifton, NJ) 1089, 143-158 (2014
29. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res. 33(4), e36 (2005
30. Tatsis N, Blejer A, Lasaro MO, et al. A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Mol. Ther. 15(3), 608-617 (2007
31. Weinberg DH, Ketner G. Adenoviral early region 4 is required for efficient viral DNA replication and for late gene expression. J. Virol. 57(3), 833-838 (1986
32. Querido E, Blanchette P, Yan Q, et al. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev. 15(23), 3104-3117 (2001
33. Querido E, Morrison MR, Chu-Pham-Dang H, Thirlwell SW, Boivin D, Branton PE. Identification of three functions of the adenovirus e4orf6 protein that mediate p53 degradation by the E4orf6-E1B55K complex. J. Virol. 75(2), 699-709 (2001
34. Blanchette P, Kindsmuller K, Groitl P, et al. Control of mRNA export by adenovirus E4orf6 and E1B55K proteins during productive infection requires E4orf6 ubiquitin ligase activity. J. Virol. 82(6), 2642-2651 (2008
35. Woo JL, Berk AJ. Adenovirus ubiquitin-protein ligase stimulates viral late mRNA nuclear export. J. Virol. 81(2), 575-587 (2007
36. Dobner T, Horikoshi N, Rubenwolf S, Shenk T. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science 272(5267), 1470-1473 (1996
37. Dicks MD, Spencer AJ, Edwards NJ, et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS ONE 7(7), e40385 (2012
38. Quinn KM, Da Costa A, Yamamoto A, et al. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J. Immunol. 190(6), 2720-2735 (2013
39. Krause A, Whu WZ, Xu Y, Joh J, Crystal RG, Worgall S. Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF. Vaccine 29(11), 2131-2139 (2011
40. Dicks MD, Guzman E, Spencer AJ, et al. The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species. Vaccine 33(9), 1121-1128 (2015
41. Zhang C, Yang Y, Chi Y, et al. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71. Vaccine 33(39), 5087-5094 (2015
42. Krause A, Whu WZ, Qiu J, et al. RGD capsid modification enhances mucosal protective immunity of a non-human primate adenovirus vector expressing Pseudomonas aeruginosa OprF. Clin. Exp. Immunol. 173(2), 230-241 (2013
43. O'Hara GA, Duncan CJ, Ewer KJ, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J. Infect. Dis. 205(5), 772-781 (2012
44. Sebastian S, Gilbert SC. Recombinant modified vaccinia virus Ankara-based malaria vaccines. Expert Rev. Vaccines 15(1), 91-103 (2016
45. De Barra E, Hodgson SH, Ewer KJ, et al. A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. PLoS ONE 9(12), e115161 (2014
46. Sheehy SH, Duncan CJ, Elias SC, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS ONE 7(2), e31208 (2012
47. Biswas S, Choudhary P, Elias SC, et al. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. PLoS ONE 9(9), e107903 (2014
48. A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and with MVA RH5. https://clinicaltrials.gov
49. Hodgson SH, Choudhary P, Elias SC, et al. Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a Phase 1a clinical trial. Mol. Ther. 22(12), 2142-2154 (2014
50. A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S. https://clinicaltrials.gov
51. A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S. https://clinicaltrials.gov
52. Hayton EJ, Rose A, Ibrahimsa U, et al. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind Phase I trial. PLoS ONE 9(7), e101591 (2014
53. Safety Study of ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy Adults. https://clinicaltrials.gov
54. Green CA, Scarselli E, Sande CJ, et al. Chimpanzee adenovirus-and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci. Transl. Med. 7(300), 300ra126 (2015
55. Swadling L, Capone S, Antrobus RD, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci. Transl. Med. 6(261), 261ra153 (2014
56. Ledgerwood JE, Dezure AD, Stanley DA, et al. Chimpanzee adenovirus vector Ebola vaccine -preliminary report. N. Engl. J. Med. doi: 10.1056/NEJMoa1410863 (2014) (Epub ahead of print
57. Rampling T, Ewer K, Bowyer G, et al. A monovalent chimpanzee adenovirus ebola vaccine -preliminary report. N. Engl. J. Med. doi: 10.1056/NEJMoa1411627 (2015) (Epub ahead of print
58. Kennedy SB, Neaton JD, Lane HC, et al. Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: design, procedures, and challenges. Clin Trials doi: 10.1177/1740774515621037 (2016) (Epub ahead of print
59. Antrobus RD, Coughlan L, Berthoud TK, et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol. Ther. 22(3), 668-674 (2014
60. VAccination in Prostate caNCEr (VANCE). https://clinicaltrials.gov
61. Tapia MD, Sow SO, Lyke KE, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a Phase 1, single-blind, randomised trial, a Phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis. 16(1), 31-42 (2016
62. De Santis O, Audran R, Pothin E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, Phase 1/2a study. Lancet Infect. Dis. doi: 10.1016/S1473-3099(15)00486-00487 (2015) (Epub ahead of print
63. Ewer K, Rampling T, Venkatraman N, et al. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N. Engl. J. Med. 374(17), 1635-1646 (2016
64. Partnership for Research on Ebola Vaccines in Liberia (PREVAIL). https://clinicaltrials.gov
65. Green CA, Scarselli E, Voysey M, et al. Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, Phase 1 clinical trial in healthy adults. BMJ Open 5(10), e008748 (2015
66. Cappuccini F, Stribbling S, Pollock E, Hill AV, Redchenko I. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer. Cancer Immunol. Immunother. doi: 10.1007/s00262-016-1831-1838 (2016) (Epub ahead of print